Bedside manufacturing of engineered stem cells using gene therapy foam

Area of Science:

• Biotechnology
• Hematology
• Gene Therapy

Background:

• Hematopoietic stem cell (HSC) gene therapies offer promise for genetic disorders but face challenges like cost and accessibility.
• Current methods require novel technologies to improve efficiency and patient access.

Purpose of the Study:

• To develop a bedside cell manufacturing strategy for HSC gene therapy.
• To improve the efficiency and accessibility of HSC gene therapies.

Main Methods:

• A novel methylcellulose-based foam was developed for gene therapy delivery.
• The foam was mixed with bone marrow aspirate concentrate for direct injection into the marrow.
• Genetic reprogramming of CD34+ HSCs was performed using low vector doses within the foam.

Main Results:

• Highly efficient genetic reprogramming of CD34+ HSCs was achieved within the foam.
• The foam retained vector at the injection site, boosting local gene transfer into progenitor cells.
• The method demonstrated compatibility with human bone marrow aspirate and minimized off-target events.

Conclusions:

• The foam-based technology enables efficient HSC gene therapy at the bedside.
• This approach could lower costs and improve accessibility of gene therapies for genetic disorders.
• Outpatient administration in regional hospitals is feasible, enhancing treatment reach.